Inhibitors of the NOS enzymes: A patent review

IDrugs

Volumn 6, Issue 1, 2003, Pages 57-65

  Mete, Antonio ^a   Connolly, Stephen ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Inhibitor; Nitric oxide; Nitric oxide synthase; NOS

Indexed keywords

1,2 BENZOTHAIZINE DERIVATIVE; 1,4 BENZOXAXINE DERIVATIVE; 2 AMINOTHIAZOLINE DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 AMINOMETHYLPHENYLAMIDINE; 4 AMINOBUTOXYBENZONITRILE DERIVATIVE; 4,6 DIMETHYL 2 AMINOPYRIDINE; AMIDINE; AMINE; AMINOGUANIDINE; AMINOPTERIDINE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; GW 273629; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; IMIDAZOLE DERIVATIVE; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PIPERAZINE DERIVATIVE; PYRANCARBOXYLIC ACID DERIVATIVE; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; SPIROQUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; NITRIC OXIDE;

ANTIOXIDANT ACTIVITY; ARTHRITIS; DIMERIZATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG INHIBITION; DRUG LEGISLATION; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SYNTHESIS; HALF LIFE TIME; HUMAN; INFLAMMATION; IRRITABLE COLON; NEUROPATHIC PAIN; NONHUMAN; PATENT; REVIEW; SEPTIC SHOCK; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM;

ANIMALS; DRUG INDUSTRY; ENZYME INHIBITORS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PATENTS;

EID: 0041519221     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Crane BR, Arvai AS, Ghosh DK, Wu C, Getzoff ED, Stuehr DJ, Tainer JA: Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science (1998) 279:2121-2126. •• The first paper reporting the crystal structure of the iNOS dimer.
2. Pfeiffer S, Mayer B, Hemmens B: Nitric oxide: Chemical puzzles posed by a biological messenger. Angew Chem Int Ed (1999) 38:1714-1731.
3. Alderton WK, Cooper CE, Knowles RG: Nitric oxide synthases: Structure, function and inhibition. Biochem J (2001) 357:593-615. • A review covering the NOS area between 1996 and 2001.
4. G-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Crit Care Med (1999) 27:913-922.
5. Cheshire DR: Use of nitric oxide synthase inhibitors for the treatment of inflammatory disease and pain. IDrugs (2001) 4:795-803. • A review of NOS patents up to the first quarter of 2001.
6. Lowe JA: Nitric oxide synthase inhibitors: Recent patent activity. IDrugs (2000) 3:63-72. • A review of NOS patents up to the first quarter of 2000.
7. Hölscher C: Nitric oxide, the enigmatic neuronal messenger: Its role in synaptic plasticity. Trends Neurosci (1997) 20:298-303.
8. De Alba Gonzalez J, Clayton NM, Collins SD, Knowles RG: Role of inducible isoform of nitric oxide synthase (iNOS) in a model of established inflammatory pain in the rat. Br J Pharmacol (2001) 134:14P.
9. 2 and reduced early thermal hyperalgesia in iNOS-deficient mice. J Neurosci (2000) 20:6714-6720.
10. Koarai A, Ichinose M, Sugiura H, Yamagata S, Hattori T, Shirato K: Allergic airway hyperresponsiveness and eosinophil infiltration is reduced by a selective iNOS inhibitor, 1400W, in mice. Pulm Pharmacol Ther (2000) 13:267-275.
11. Redington AE, Meng QH, Springall DR, Evans TJ, Créminon C, Maclouf J, Holgate ST, Howarth PH, Polak JM: Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment. Thorax (2001) 56:351-357.
12. Perreault M, Marette A: Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med (2001) 7:1138-1143.
13. Tran MH, Yamada K, Olariu A, Ren XH, Miyamato Y, Nabeshima T: Involvement of nitric oxide in pathogenesis of Alzheimer's disease animal model and neuroprotective effects of iNOS inhibitors. Society for Neuroscience Annual Meeting, New Orleans, LA, USA (2000) 26:Abs 762.8.
14. Law A, Gauthier S, Quirion R: Neuroprotective and neurorescuing effects of isoform-epecific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against β-amytoid toxicity. Br J Pharmacol (2001) 133:1114-1124.
15. Reilly CM, Farrelly LW, Viti D, Redmond ST, Hutchison F, Ruiz P, Manning P, Connor J, Gilkeson GS: Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int (2002) 61:839-846.
16. Chatterjee PK, Patel NS, Kvale EO, Cuzzocrea S, Brown PA, Stewart KN, Mota-Filipe H, Thiemermann C: Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury. Kidney Int (2002) 61:862-871.
17. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS: Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res (2002) 62:165-170.
18. Reif DW, McCarthy DJ, Cregan E, Macdonald JE: Discovery and development of neuronal nitric oxide synthase inhibitors. Free Radic Biol Med (2000) 28:1470-1477.
19. Cuzzocrea S, Chatterjee PK, Mazzon E, McDonald MC, Dugo L, Di Paolo R, Serraino I, Britti D, Caputi AP, Thiemermann C: Beneficial effects of GW-274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol (2002) 453:119-129.
20. Whittle BJR: Nitric oxide based drug therapy - William Harvey Research Conference. IDrugs (2002) 5:508-510.
21. Holdcroft A: Pain therapeutics for the new millennium - SMi Conference. IDDB Meeting Report (2001).
22. 6-(1-iminoethyl) lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitor. J Med Chem (2002) 45:1686-1689. • Describes L-NILTA, a potential investigational compound.
23. Werner U, Brune K, Layh B, Guehring H: Determination of L-iminoethyl-L-lysine in serum by liquid chromatography. J Chromatogr B (2000) 749:35-40.
24. Pitzele B, Hallinan A, Tsymbalov S, Dorn C, Gerome G, Moore W, Connor J, Branson L, Webber K, Toth M, Hansen D, Manning P: Compounds related to the selective iNOS inhibitor N6-(1-iminoethyl)-L-lysine (L-NIL). Nitric Oxide (2002) 6:449-450.
25. McMillan K, Adler M, Auld DS, Baldwin JJ, Blasko E, Browne LJ, Chelsky D, Davey D, Dolle RE, Eagen KA, Erickson S et al: Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci USA (2000) 97:1506-1511.
26. Blasko E, Glaser CB, Devlin JJ, Xia W, Feldman RI, Polokoff MA, Phillips GB, Whitlow M, Auld DS, McMillan K, Ghosh S et al: Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J Biol Chem (2001) 277:295-302.
27. AVENTIS PHARMA SA (Carry J-C, Damour D, Guyon C, Mignani S, Bacque E, Bigot A): 4,5-Dihydro-thiazo-2-ylamine derivatives and their use as NO-synthase inhibitors. WO-00193867 (2001).
28. AVENTIS PHARMA SA (Carry J-C, Damour D, Guyon C, Mignani S, Bigot A, Bacque E, Tabart M): 2-Aminothiazoline derivatives end their use as NO-synthase inhibitors. WO-00194325 (2001).
29. THE WELLCOME FOUNDATION LTD (Garvey EP, Tanoury GJ, Oplinger JA, Furfine ES): Enzyme inhibitors. WO-09412165 (1994).
30. GD SEARLE & CO (Hansen D, Currie M, Hallinan E, Fok K, Hagen T, Bergmanis A, Kramer S, Lee L, Metz S, Moore W, Peterson K et al): Amidino derivatives useful as nitric oxide synthase inhibitors. WO-09511231 (1995).
31. MERCK & CO INC (Shah SK, Grant SK, Maccoss M, Shankaran K, Qi H, Guthikonda RN): Substituted heterocycles as inhibitors of nitric oxide synthase. WO-09614842 (1996).
32. SCHERING AG (Hölscher P, Rehwinkel H, Jaroch S, Sülzle D, Hilmann M, Burton GA, McDonald FM): Benzoxazine and benzothiazine derivatives and the use thereof in medicaments. WO-00114347 (2001).
33. SCHERING AG (Rehwinkel H, Hölscher P, Jaroch S, Sülzle D, Hillmann M, Burton GA, McDonald FM): Benzoxazine and benzothiazine derivatives and the use thereof in medicaments. WO-00181323 (2001).
34. SCHERING AG (Hölscher P, Jautelat R, Rehwinkel H, Jaroch S, Sülzle D, Hillmann M, Burton GA, McDonald FM): Benzoxazine derivatives and benzothiazine derivatives having NOS inhibitory and antioxidant properties. WO-00181324 (2001).
35. ASTRAZENECA AB (Mattes K, Murray R, Phillips E, Schmitthenner H): Amidine derivatives which are inhibitors of nitric oxide synthase. WO-00146170 (2001).
36. ASTRAZENECA AB (Chen D, Empfield J, Macdonald J, Mattes K, Murray R, Phillips E, Schmitthenner H): Amidine derivatives which are inhibitors of nitric oxide synthase. WO-00146171 (2001).
37. ASTRAZENECA AB (Chen D, Empfield J, Mattes K, Murray R, Phillips E): Amidine derivatives which are inhibitors of nitric oxide synthase. WO-00220511 (2002).
38. ASTRAZENECA AB (Walpole C, Yang H): Novel compounds. WO-00158867 (2001).
39. ASTRAZENECA AB (Cheshire D, Connolly S, Cox D, Hamley P, Mete A, Pimm A): Novel use of phenylheteroalkylamine derivatives. WO-00162704 (2001).
40. ASTRAZENECA AB (Birkinshaw T, Cheshire D, Mete A): Novel phenylheteroalkylamine derivatives. WO-00162713 (2001).
41. ASTRAZENECA AB (Cheshire D, Connolly S, Cox D, Mete A): Novel phenylheteroalkylamine derivatives. WO-00162714 (2001).
42. ASTRAZENECA AB (Cheshire D, Connolly S, Cox D, Millichip I): Novel use of phenylheteroalkylamine derivatives. WO-00162721 (2001).
43. ASTRAZENECA AB (Cheshire D, Luker T, Mete A): Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors. WO-00212187 (2002).
44. CHUGAI SEIYAKU KABUSHIKI KAISHA (Honda T, Makino T): Aniline derivatives. WO-00183429 (2001).
45. SOCIETÉ DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (Chabrier de Lassauniere PE, Auvin S, Bigg D, Auguet M, Harnett J): Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them. US-06335445 (2002)
46. SOCIETÉ DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (Auvin S, Harnett J, Chabrier de Lassauniere PE): Amino acid derivatives and their use as medicines. WO-00185677 (2001).
47. GLAXO GROUP LTD (Beams RM, Drysdale MJ, Franzman KW, Frend AJ, Hodson HF, Knowles RG, Rees DD, Sawyer DA): Nitric oxide synthase inhibitors. WO-09830537 (1998).
48. THE WELLCOME FOUNDATION LTD (Beams RM, Hodson HF, Palmer RM): Amidino derivatives and their use as nitric oxide synthase inhibitors. WO-09313055 (1993).
49. GLAXO GROUP LTD (Box D, Colclough D, Gillies I, Loft MS, Moore R): Nitric oxide synthase inhibitor phosphate salt. WO-00250021 (2002). • Describes the preparation of a non-hygroscopic salt of a potential investigational compound.
50. GD SEARLE & CO (Hansen DW Jr, Bergmanis AA, Hagen TJ, Hallinan EA, Kramer SW, Metz S, Peterson KB, Pitzele BS, Tjoeng F, Toth MV, Trivedi M et al): Imidazoles useful as nitric oxide synthase inhibitors. US-06344473 (2002).
51. PHARMACIA CORP (Webber R, Awasthi A, Bergmanis A, Durley R, Fok K, Ganser S, Hagen T, Hallinan A, Hansen D, Hickory BS, Manning PT et al): Amidino compounds useful as nitric oxide synthase inhibitors. WO-00172702 (2001).
52. PHARMACIA CORP (Webber R, Awasthi A, Bergmanis A, Durley R, Ganser S, Hagen T, Hallinan A, Hansen D, Hickory B, Moormann AE, Pitzele BS et al): Amidino compound and salts thereof useful as nitric oxide synthase inhibitors. WO-00172703 (2001). • Describes the preparation of a large number of salts of a potential investigational compound.
53. PHARMACIA CORP (Awasthi A, Franczyk T, Hansen D, Moormann A, Snyder J, Trivedi M, Webber R): Hexahydro-7-1H- azepin-2-yl-hexanoic acid derivatives as inhibitors of inducible NO synthase. WO-00210139 (2002).
54. PHARMACIA CORP (Awasthi A, Hansen D, Manning P, Pitzele B, Sikorski J, Toth M, Trivedi M, Webber R): Halogenated 2-amino-3,4-heptenoic acid derivatives useful as nitric oxide synthase inhibitors. WO-00178654 (2001).
55. PHARMACIA CORP (Awasthi AK, Hansen DW Jr, Manning PT, Sikorski JA, Webber RK): Halogenated 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors. WO-00179156 (2001).
56. PHARMACIA CORP (Grapperhaus ML, Sikorski JA, Awasthi AK, Wang LJ, Pitzele BS, Hansen DW Jr, Manning PT): Halogenated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors. WO-00178719 (2000).
57. PHARMACIA CORP (Hansen D Jr, Trivedi JS, Toth MV, Webber RK, Pitzele BS, Awasthi AK, Sikorski J, Moorman AE): 2-Amino-2-alkyl- 4-heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors. WO-00222557 (2002).
58. PHARMACIA CORP (Hansen D Jr, Webber RK, Pitzele BS, Awasthi AK, Sikorski J, Trivedi M, Moorman AE): 2-Amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors. WO-00222558 (2002).
59. PHARMACIA CORP (Durley RC, Sikorski J, Hansen D Jr, Promo MA, Webber RK, Pitzele BS, Awasthi AK, Moorman AE): 2-Amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors. WO-00222559 (2002).
60. PHARMACIA CORP (Hansen D Jr, Webber RK, Pitzele BS, Awasthi AK): 2-Amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors. WO-00222561 (2002).
61. PHARMACIA CORP (Hansen D Jr, Webber RK, Pitzele BS, Sikorski J, Massa MA, Hagen TJ, Grapperhaus M, Wang L, Bergmanis A, Kramer S, Hallinan E): 2-Amino-2-alkyl-5-heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors. WO-00222562 (2002).
62. GD SEARLE & CO (Currie MG, Webber K, Tjoeng FS, Fok KF): Amidino derivatives useful as nitric oxide synthase inhibitors. WO-09525717 (1995).
63. MONSANTO COMPANY (Webber RK, Reuppel ML, Hansen DW Jr, Hallinan EA, Hagen TJ, Pitzele B): Oligomeric amino acid derivatives useful as nitric oxide synthase inhibitors. WO-00105748 (2001).
64. BERLEX LABORATORIES INC (Arnaiz DO, Baldwin JJ, Davey DD, Devlin JJ, Dolle RE III, Erickson SD, McMillan K, Morrissey MM, Ohlmeyer HH, Pan G, Paradkar VM et al): N-Heterocyclic derivatives as NOS inhibitors. WO-09837079 (1998).
65. BERLEX LABORATORIES INC (Arnaiz D, Baldwin J, Davey D, Devlin J, Dolle R, Erickson S, McMillan K, Morrissey M, Ohlmeyer M, Pan G, Paradkar V et al): N-Heterocyclic derivatives as NOS inhibitors. WO-00114371 (2001).
66. SCHERING AG (Davey D, Pham E, Phillips GB, Xu W): N-Heterocyclic derivatives as NOS inhibitors. WO-00172744 (2001).
67. FUJISAWA PHARMACEUTICAL CO LTD (Yatabe T, Itoh Y, Inoue T, Hamashima H, Shima I, Ohne K, Yoshihara K, Oku T, Yatabe Y): New amide compounds. WO-09827108 (1998).
68. FUJISAWA PHARMACEUTICAL CO LTD (Shima I, Ohkawa T, Ohne K, Sato K, Ishibashi N, Imamura K): Substituted dipeptides having NOS inhibiting activity. WO-00132690 (2001).
69. FUJISAWA PHARMACEUTICAL CO LTD (Ishii Y, Ueda Y, Iwami M, Arakawa H, Notsu Y): Method of screening inducible nitric oxide synthase activation inhibitor. WO-00166791 (2001).
70. MAXIA PHARMACEUTICALS INC (Pfahl M, Tachdjian C, Al-Shamma HA, Fanju A, Pleynet DP, Spruce LW): Benzylidene- thiazolidinediones and analogues and their use in the treatment of inflammation. WO-00116123 (2001).
71. VASOPHARM BIOTECH GMBH (Pfleiderer W, Schmidt H, Fröhlich L, Kotsonis P, Taghavi-Moghadam S): N-Substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent. WO-00121619 (2001).
72. GRÜNENTHAL GMBH (Maul C, Sundermann B, Hennies H, Schneider J, Gerlach M): Tert-Butyl-(7-methyl-imidazo[1,2-a] pyridine-3-yl)-amine derivatives. WO-00127109 (2001).
73. GRÜNENTHAL GMBH (Sundermann B, Maul C, Hennies H, Schneider J): Use of substituted imidazo[1,2-a]pyridine, imidazo[1,2-a]pyrimidine and imidazo[1,2-a] pyrazine-3-yl-amine derivatives for producing NOS-inhibiting medicaments. WO-00230428 (2002).
74. TAKEDA CHEMICAL INDUSTRIES LTD (Tamura T, Ichikawa T, II M): Substituted aromatic-ring compounds, process for producing the same and use. WO-00110826 (2001).